Clinical Trial Update: Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating dostarlimab as neoadjuvant therapy for patients with MMRd/MSI-H endometrial cancer (Stage II-III). The trial status is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)

Snippet

Sponsor: Grupo Español de Investigación en Cáncer de Ovario | Conditions: MMRd/MSI-H Stage II-III Endometrial Cancer | Phase 2 | Status: NOT_YET_RECRUITING